Literature DB >> 17901710

Could neutrophil-gelatinase-associated lipocalin and cystatin C predict the development of contrast-induced nephropathy after percutaneous coronary interventions in patients with stable angina and normal serum creatinine values?

H Bachorzewska-Gajewska1, J Malyszko, E Sitniewska, J S Malyszko, K Pawlak, M Mysliwiec, S Lawnicki, M Szmitkowski, S Dobrzycki.   

Abstract

The value of neutrophil-gelatinase-associated lipocalin (NGAL) was highlighted as a novel biomarker for the detection of acute renal failure. We tested the hypothesis whether NGAL could represent an early biomarker of contrast-induced nephropathy (CIN) in 100 patients with normal serum creatinine values undergoing percutaneous coronary interventions (PCI). In addition, we assessed serum and urinary NGAL in relation to cystatin C, estimated glomerular filtration rate, and serum and urinary creatinine in these patients. We measured urinary and serum NGAL values before and 2, 4, 8, 24, and 48 h after the PCI. We found a significant rise in serum NGAL levels 2, 4, and 8 h after the PCI and in urinary NGAL values 4, 8, and 24 h after a PCI procedure. Cystatin C rose significantly 24 h after the procedure. The prevalence of CIN was 11%. The NGAL levels were significantly higher 2 h after the PCI (serum NGAL) or 4 h after the PCI (urinary NGAL), whereas the cystatin C values were higher only 8 and 24 h after a PCI procedure in patients with CIN. In multivariate analysis, only serum creatinine was a predictor of serum NGAL before a PCI. NGAL may represent a sensitive early biomarker of renal impairment after PCI. Serum creatinine level, the presence of diabetes, and the duration of the PCI may affect serum NGAL values and kidney function following a PCI procedure. (c) 2007 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17901710     DOI: 10.1159/000109102

Source DB:  PubMed          Journal:  Kidney Blood Press Res        ISSN: 1420-4096            Impact factor:   2.687


  35 in total

1.  Rosuvastatin attenuated contrast-induced nephropathy in diabetes patients with renal dysfunction.

Authors:  Bing Qiao; Jie Deng; Yi Li; Xiaozeng Wang; Yaling Han
Journal:  Int J Clin Exp Med       Date:  2015-02-15

Review 2.  Neutrophil gelatinase-associated lipocalin--an emerging troponin for kidney injury.

Authors:  Prasad Devarajan
Journal:  Nephrol Dial Transplant       Date:  2008-09-22       Impact factor: 5.992

Review 3.  Perspective on Clinical Application of Biomarkers in AKI.

Authors:  Chirag R Parikh; Sherry G Mansour
Journal:  J Am Soc Nephrol       Date:  2017-02-20       Impact factor: 10.121

4.  Neutrophil gelatinase-associated lipocalin in adult septic patients with and without acute kidney injury.

Authors:  Johan Mårtensson; Max Bell; Anders Oldner; Shengyuan Xu; Per Venge; Claes-Roland Martling
Journal:  Intensive Care Med       Date:  2010-04-16       Impact factor: 17.440

5.  Emerging urinary biomarkers in the diagnosis of acute kidney injury.

Authors:  Prasad Devarajan
Journal:  Expert Opin Med Diagn       Date:  2008-04

Review 6.  Renalase and Biomarkers of Contrast-Induced Acute Kidney Injury.

Authors:  Maciej T Wybraniec; Katarzyna Mizia-Stec
Journal:  Cardiorenal Med       Date:  2015-09-19       Impact factor: 2.041

7.  Kidney Biomarkers of Injury and Repair as Predictors of Contrast-Associated AKI: A Substudy of the PRESERVE Trial.

Authors:  Chirag R Parikh; Caroline Liu; Maria K Mor; Paul M Palevsky; James S Kaufman; Heather Thiessen Philbrook; Steven D Weisbord
Journal:  Am J Kidney Dis       Date:  2019-09-20       Impact factor: 8.860

8.  Serum neutrophil gelatinase-associated lipocalin at inception of renal replacement therapy predicts survival in critically ill patients with acute kidney injury.

Authors:  Philipp Kümpers; Carsten Hafer; Alexander Lukasz; Ralf Lichtinghagen; Korbinian Brand; Danilo Fliser; Robert Faulhaber-Walter; Jan T Kielstein
Journal:  Crit Care       Date:  2010-02-01       Impact factor: 9.097

9.  Prevention of contrast-induced nephropathy with prostaglandin E1 in high-risk patients undergoing percutaneous coronary intervention.

Authors:  Wen-Hua Li; Dong-Ye Li; Wen-Hao Qian; Jia-Li Liu; Tong-Da Xu; Hong Zhu; Hai-Yan He
Journal:  Int Urol Nephrol       Date:  2014-02-26       Impact factor: 2.370

Review 10.  Preventing contrast-induced nephropathy: problems, challenges and future directions.

Authors:  Richard Solomon
Journal:  BMC Med       Date:  2009-05-13       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.